Akebia Therapeutics (CH:AX9)
NASDAQ:AX9
AX9 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Clinical DifferentiationAnalyst believes outcome-focused clinical data and head-to-head comparisons versus existing therapies could increase payer and provider confidence and strengthen the drug's market differentiation.
Dialysis Commercialization And AdherenceAnalyst highlights commercial supply agreements with major dialysis organizations and an in-center dosing protocol that improved first refill adherence, supporting higher patient utilization of the anemia therapy.
Pipeline Expansion Into Rare Kidney DiseasesAnalyst points to a diverse pipeline including praliciguat and a tissue-targeted complement inhibitor that target rare kidney conditions and novel mechanisms, offering potential growth beyond the core anemia franchise.
Bears Say
Clinical Trial Outcome RiskAnalyst notes that commercial and clinical success depends on upcoming trial results and published comparative evidence, and failure to demonstrate clear differentiation could limit market uptake.
Generic Competition PressureAnalyst cautions that current marketed drugs face generic competition, which could reduce revenues and pose a headwind to the company's financial outlook.
Inventory And Near-term Revenue ImpactAnalyst lowered the price target after adjusting near-term revenue expectations to reflect an inventory impact tied to a dosing protocol at a large dialysis provider, signaling potential short-term revenue weakness.
Akebia Therapeutics News
AX9 FAQ
What was Akebia Therapeutics’s price range in the past 12 months?
Currently, no data Available
What is Akebia Therapeutics’s market cap?
Akebia Therapeutics’s market cap is CHF199.07M.
When is Akebia Therapeutics’s upcoming earnings report date?
Akebia Therapeutics’s upcoming earnings report date is Jul 30, 2026 which is in 53 days.
How were Akebia Therapeutics’s earnings last quarter?
Akebia Therapeutics released its earnings results on May 07, 2026. The company reported -$0.023 earnings per share for the quarter, missing the consensus estimate of -$0.022 by -$0.002.
Is Akebia Therapeutics overvalued?
According to Wall Street analysts Akebia Therapeutics’s price is currently Undervalued.
Does Akebia Therapeutics pay dividends?
Akebia Therapeutics does not currently pay dividends.
What is Akebia Therapeutics’s EPS estimate?
Akebia Therapeutics’s EPS estimate is -0.03.
How many shares outstanding does Akebia Therapeutics have?
Currently, no data Available
What happened to Akebia Therapeutics’s price movement after its last earnings report?
Akebia Therapeutics reported an EPS of -$0.023 in its last earnings report, missing expectations of -$0.022. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Akebia Therapeutics?
Currently, no hedge funds are holding shares in CH:AX9
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Akebia Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-74.66%
12-Months-Change
Fundamentals
Return on Equity
-62.72%
Trailing 12-Months
Asset Growth
16.87%
Trailing 12-Months
Company Description
Akebia Therapeutics
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
AX9 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call highlights strong commercial momentum for Vafseo (32% revenue growth, ~60% patient growth quarter-over-quarter, higher prescriber engagement and improved adherence under observed dosing) and meaningful pipeline progress with supportive clinical data and upcoming readouts. However, legacy product Auryxia faces notable generic-driven revenue decline (≈-17%), the company swung to a net loss in the quarter, experienced sizable inventory write-downs and higher operating expenses, and cash declined q/q. While the launch and clinical developments are encouraging and provide a clear growth narrative, the near-term financial headwinds and competitive/enrollment risks temper the outlook.View all CH:AX9 earnings summariesAX9 Stock 12 Month Forecast
Average Price Target
$3.68
Oruka Therapeutics
―
Theravance Biopharma
―
Vir Biotechnology
―
ProKidney
―
ArriVent BioPharma, Inc.
―
Options Prices
Currently, No data available
---